Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli
Articolo
Data di Pubblicazione:
2022
Citazione:
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli / Della-Torre, E.; Campochiaro, C.; Cavalli, G.; De Luca, G.; Ciceri, F.; Zangrillo, A.; Dagna, L.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 81:9(2022), pp. E158-e158. [Epub ahead of print] [10.1136/annrheumdis-2020-218612]
Tipologia CRIS:
1.1.1 Articolo in rivista - Review
Keywords:
Anti-inflammatory agents; Cytokines; Inflammation; Interleukin 1 receptor antagonist protein; Non-steroidal; Therapeutics
Elenco autori:
Della-Torre, E.; Campochiaro, C.; Cavalli, G.; De Luca, G.; Ciceri, F.; Zangrillo, A.; Dagna, L.
Link alla scheda completa:
Pubblicato in: